Announcement PDF ASX Announcement 14th January 2025 Long Term Agreement Signed with Newfoundland for HIV Self-Testing SYDNEY, Australia, January 14th 2025 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce it has executed a new long-term supply agreement with existing distribution partner Newfoundland Diagnostics Limited (Newfoundland), worth approximately A$5.44m over five years. The new agreement, which is effective immediately and runs until 30 June 2030, grants Newfoundland exclusive distribution rights to supply Atomo’s test in the UK and non-exclusive rights for the EU and Colombia. The agreement comes with an upfront order for 50,000 tests to be manufactured by Atomo during this quarter. Newfoundland has been supplying Atomo’s HIV Self-Test, branded Newfoundland, in the UK and a number of other European countries for over a year, with more recent expansion into markets such as Eastern Europe and Colombia under a prior agreement (ASX Release date 14th June 2023: Atomo and Newfoundland sign agreement for HIV testing in Europe). Newfoundland branded product has been successfully launched in the UK’s two leading retail chains, Boots Pharmacies and Tesco Supermarkets, with the most recent purchase order supporting product launch in a number of Eastern European countries where HIV infection rates and demand for testing continues to grow. Atomo’s CEO John Kelly said “we are excited about building a long-term relationship with Newfoundland. They have done an excellent job getting our HIV tests on the shelves of the leading retailers in Europe and this partnership gives us the perfect channel to launch other Atomo tests, including the world’s first Active Syphilis self-test being currently developed with funding from the Australian government”. Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 Newfoundland CEO, Mr Frederick Manduca said, “Newfoundland are delighted to be continuing our partnership with Atomo Diagnostics. We have had great success distributing the test and working with partners such as the Terrence Higgins Trust and major retailers in the UK. We are excited to continue this success in the coming years by furthering our distribution into new channels and international territories.” For more information, please contact: John Kelly Atomo Diagnostics john.kelly@atomodiagnostics.com Phone: +61 401 922 279 This announcement was authorised by the Managing Director & CEO. About Atomo Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial differentiation, as well as the early detection of pregnancy. See more at www.atomodiagnostics.com Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040